Overview

Phase 2 Basket Trial of Nab-sirolimus in Patients With Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1)

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

A Phase 2 multi-center open-label basket trial of ABI-009 (nab sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Phase:

Phase 2

Details

Lead Sponsor:

Aadi, LLC

Treatments:

Sirolimus